Acquisition of Sexually Transmitted Infections among Women Using a Variety of Contraceptive Options: A prospective Study among High-risk African Women

Flavia Matovu Kiweewa, Elizabeth Brown, Anu Mishra, Gonasagrie Nair, Thesla Palanee-Phillips, Nyaradzo Mgodi, Clemensia Nakabiito, Nahida Chakhtoura, Sharon L Hillier, Jared M Baeten, MTN-020/ASPIRE Study Team, Lydia Soto-Torres, Katie Schwartz, Bonus Makanani, Francis Martinson, Linda-Gail Bekker, Vaneshree Govender, Felix Mhlanga, Flavia Matovu Kiweewa, Elizabeth Brown, Anu Mishra, Gonasagrie Nair, Thesla Palanee-Phillips, Nyaradzo Mgodi, Clemensia Nakabiito, Nahida Chakhtoura, Sharon L Hillier, Jared M Baeten, MTN-020/ASPIRE Study Team, Lydia Soto-Torres, Katie Schwartz, Bonus Makanani, Francis Martinson, Linda-Gail Bekker, Vaneshree Govender, Felix Mhlanga

Abstract

Introduction: In many African settings, women concurrently face substantial risk of human immunodeficiency virus type 1 (HIV-1) infection, sexually transmitted infections (STIs) and unintended pregnancies. Few studies have evaluated STI risk among users of hormonal implants and copper intrauterine devices (IUDs) although these long-acting reversible contraceptive methods are being promoted widely because of their benefits. Within a prospective study of women at risk for HIV-1, we compared the risk of acquisition of Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis among women using different contraceptive methods.

Methods: MTN-020/ASPIRE was a randomized trial of the dapivirine vaginal ring for HIV-1 prevention among 2629 women aged 18 to 45 years from Malawi, South Africa, Uganda and Zimbabwe, of whom 2264 used copper IUDs or progestin-based injectables or implants during follow-up. Screening for the above STIs occurred semi-annually.

Results: Over 3440 person-years of follow-up, 408 cases of C. trachomatis (incidence 11.86/100 person-years), 196 of N. gonorrhoeae (5.70/100 person-years) and 213 cases of T. vaginalis (6.19/100 person-years) were detected. C. trachomatis and N. gonorrhoeae incidence were not significantly different across contraceptive methods. T. vaginalis incidence was significantly higher for copper IUD users compared to depot medroxyprogesterone acetate (DMPA), implant and norethisterone enanthate users.

Conclusion: Among African women at high HIV-1 risk, STIs were common. Risk of cervical infections did not differ across contraceptive methods. Significantly higher rates of T. vaginalis were observed among progestin-based methods compared to copper IUD users. Overall, these findings call for more intensive routine screening for STIs, and they support current World Health Organization guidance that women should have a wide range of contraceptive options.

Trial registration: ClinicalTrials.gov NCT01617096.

Keywords: chlamydia; gonorrhoea; hormonal contraception; sexually transmitted diseases; trichomoniasis.

© 2019 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.

References

    1. Hu DJ, Buvé A, Baggs J, van der Groen G, Dondero TJ. What role does HIV‐1 subtype play in transmission and pathogenesis? An epidemiological perspective AIDS. 1999;13:873–81.
    1. Newman L, Rowley J, Vander Hoorn S, Wijesooriya NS, Unemo M, Low N, et al. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. PLos One. 2015;10(12):e0143304.
    1. Schuchardt L, Rupp J. Chlamydia trachomatis as the cause of infectious infertility: acute, repetitive or persistent long‐term infection? Curr Top Microbiol Immunol. 2016; 412:159–82.
    1. Polis CB, Curtis KM, Hannaford PC, Phillips SJ, Chipato T, Kiarie JN, et al. An updated systematic review of epidemiological evidence on hormonal contraceptive methods and HIV acquisition in women. AIDS. 2016;30(17):2665.
    1. Noguchi LM, Richardson BA, Baeten JM, Hillier SL, Balkus JE, Chirenje ZM, et al. Risk of HIV‐1 acquisition among women who use different types of injectable progestin contraception in South Africa: a prospective cohort study. Lancet HIV. 2015;2(7):e279–87.
    1. Jones HE, van de Wijgert JH. DMPA use and HIV acquisition: time to switch to NET‐EN? Lancet HIV. 2015;2(7):e263–4.
    1. Ralph LJ, Gollub EL, Jones HE. Hormonal contraceptive use and women's risk of HIV acquisition: priorities emerging from recent data. Curr Opin Obstet Gynecol. 2015;27(6):487–95.
    1. Hapgood JP, Kaushic C, Hel Z. Hormonal contraception and HIV‐1 acquisition: biological mechanisms. Endocr Rev. 2018;39:36–78.
    1. Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, et al. Use of hormonal contraceptives and risk of HIV‐1 transmission: a prospective cohort study. Lancet Infect Dis. 2012;12(1):19–26.
    1. Richardson BA, Martin HL Jr, Stevens CE, Hillier SL, Mwatha AK, Chohan BH, et al. Use of nonoxynol‐9 and changes in vaginal lactobacilli. J Infect Dis. 1998;178:441–5.
    1. Morrison CS, Chen P‐L, Kwok C, Baeten JM, Brown J, Crook AM, et al. Hormonal contraception and the risk of HIV acquisition: an individual participant data meta‐analysis. PLoS Med. 2015;12(1):e1001778.
    1. Balkus JE, Brown ER, Hillier SL, Coletti A, Ramjee G, Mgodi N, et al. Oral and injectable contraceptive use and HIV acquisition risk among women in four African countries: a secondary analysis of data from a microbicide trial. Contraception. 2016;93(1):25–31.
    1. Kiweewa FM, Noguchi L, Richardson B, Balkus J, Kamira B, Gati BM, et al. Prevalent and incident gonorrhea and chlamydia infections among oral contraceptive and depot medroxyprogesterone acetate users in MTN‐003 (VOICE). AIDS Res Hum Retroviruses. 2014;30 S1:A278.
    1. Brahmbhatt H, Musoke R, Makumbi F, Kigozi G, Serwadda D, Wawer M, et al. Trichomonas vaginalis incidence associated with hormonal contraceptive use and HIV infection among women in Rakai, Uganda. J Sex Transm Dis. 2014;2014:916597.
    1. Romer A, Shew ML, Ofner S, Gilliam ML, Martins SL, Fortenberry JD. Depot medroxyprogesterone acetate use is not associated with risk of incident sexually transmitted infections among adolescent women. J Adolesc Health. 2013;52(1):83–8.
    1. Borgdorff H, Verwijs MC, Wit FW, Tsivtsivadze E, Ndayisaba GF, Verhelst R, et al. The impact of hormonal contraception and pregnancy on sexually transmitted infections and on cervicovaginal microbiota in african sex workers. Sex Transm Dis. 2015;42(3):143–52.
    1. Pettifor A, Delany S, Kleinschmidt I, Miller WC, Atashili J, Rees H. Use of injectable progestin contraception and risk of STI among South African women. Contraception. 2009;80(6):555–60.
    1. Deese J, Pradhan S, Goetz H, Morrison C. Contraceptive use and the risk of sexually transmitted infection: systematic review and current perspectives. Open Access J Contracept. 2018;9:91.
    1. Baeten JM, Nyange PM, Richardson BA, Lavreys L, Chohan B, Martin HL, et al. Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study. Am J Obstet Gynecol. 2001;185(2):380–5.
    1. Erol O, Simavlı S, Derbent AU, Ayrım A, Kafalı H. The impact of copper‐containing and levonorgestrel‐releasing intrauterine contraceptives on cervicovaginal cytology and microbiological flora: a prospective study. Eur J Contracept Reprod Health Care. 2014;19(3):187–93.
    1. Baeten JM, Palanee‐Phillips T, Brown ER, Schwartz K, Soto‐Torres LE, Govender V, et al. Use of a vaginal ring containing dapivirine for HIV‐1 prevention in women. N Engl J Med. 2016;375:2121–32.
    1. World Health Organization . Guidelines on Treatment of Sexually Transmitted Infections. 2018. [cited 2018 July 31]. Available from:
    1. Morrison CS, Bright P, Wong EL, Kwok C, Yacobson I, Gaydos CA, et al. Hormonal contraceptive use, cervical ectopy, and the acquisition of cervical infections. Sex Transm Dis. 2004;31(9):561–7.
    1. Mohllajee AP, Curtis KM, Martins SL, Peterson HB. Hormonal contraceptive use and risk of sexually transmitted infections: a systematic review. Contraception. 2006;73(2):154–65.
    1. Morrison CS, Turner AN, Jones LB. Highly effective contraception and acquisition of HIV and other sexually transmitted infections. Best Pract Res Clin Obstet Gynaecol. 2009;23(2):263–84.
    1. Torok MR, Miller WC, Hobbs MM, MacDonald PD, Leone PA, Schwebke JR, et al. The association between oral contraceptives, depot‐medroxyprogesterone acetate, and trichomoniasis. Sex Transm Dis. 2009;36(6):336.
    1. Barbone F, Austin H, Louv WC, Alexander WJ. A follow‐up study of methods of contraception, sexual activity, and rates of trichomoniasis, candidiasis, and bacterial vaginosis. Am J Obstet Gynecol. 1990;163(2):510–4.
    1. Ryu J, Choi H, Min D, Ha S, Ahn M. Effect of iron on the virulence of Trichomonas vaginalis . J Parasitol. 2001;87(2):457–60.
    1. Achilles SL, Austin MN, Meyn LA, Mhlanga F, Chirenje ZM, Hillier SL. Impact of contraceptive initiation on vaginal microbiota. Am J Obstet Gynecol. 2018;218:622.e1–10.
    1. Balkus JE, Richardson BA, Rabe LK, Taha TE, Mgodi N, Kasaro MP, et al. Bacterial vaginosis and the risk of Trichomonas vaginalis acquisition among HIV‐1 negative women. Sex Transm Dis. 2014;41(2):123.
    1. Wang L‐Y, OuYang L, Tong F, Zhang X‐J, Wang C‐C, Li X, et al. The effect of contraceptive methods on reproductive tract infections risk: a cross‐sectional study having a sample of 52,481 women. Arch Gynecol Obstet. 2016;294(6):1249–56.
    1. Taneepanichskul S, Patrachai S. Effects of long‐term treatment with depot medroxy progesterone acetate for contraception on estrogenic activity. J Med Assoc Thai. 1998;81(12):944–6.
    1. Ortiz A, Hiroi M, Stanczyk F, Goebelsmann U, Mishell D Jr. Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo‐MPA. J Clin Endocrinol Metab. 1977;44(1):32–9.
    1. Louw‐du Toit R, Perkins MS, Hapgood JP, Africander D. Comparing the androgenic and estrogenic properties of progestins used in contraception and hormone therapy. Biochem Biophys Res Comm. 2017;491(1):140–6.
    1. Benova L, Cleland J, Daniele MA, Ali M. Expanding method choice in Africa with long‐acting methods: IUDs, implants or both? Int Perspect Sex Reprod Health. 2017;43(4):183–91.
    1. Alaeus A, Lidman K, Björkman A, Giesecke J, Albert J. Similar rate of disease progression among individuals infected with HIV‐1 genetic subtypes A‐D. AIDS. 1999;13:901–7.
    1. Organization WH . Hormonal contraceptive eligibility for women at high risk of HIV. 2017.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren